Cargando…

Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer

Objective: Plasma protein biomarkers could be an efficient alternative for population-based screening for early detection of colorectal cancer (CRC). The objective of this study was to evaluate and validate plasma proteins individually and as a signature for early detection of CRC. Methods: In a thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhardwaj, Megha, Gies, Anton, Weigl, Korbinian, Tikk, Kaja, Benner, Axel, Schrotz-King, Petra, Borchers, Christoph H., Brenner, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826652/
https://www.ncbi.nlm.nih.gov/pubmed/31557860
http://dx.doi.org/10.3390/cancers11101426
_version_ 1783465140889321472
author Bhardwaj, Megha
Gies, Anton
Weigl, Korbinian
Tikk, Kaja
Benner, Axel
Schrotz-King, Petra
Borchers, Christoph H.
Brenner, Hermann
author_facet Bhardwaj, Megha
Gies, Anton
Weigl, Korbinian
Tikk, Kaja
Benner, Axel
Schrotz-King, Petra
Borchers, Christoph H.
Brenner, Hermann
author_sort Bhardwaj, Megha
collection PubMed
description Objective: Plasma protein biomarkers could be an efficient alternative for population-based screening for early detection of colorectal cancer (CRC). The objective of this study was to evaluate and validate plasma proteins individually and as a signature for early detection of CRC. Methods: In a three-stage design, proteins were measured firstly by liquid chromatography/multiple reaction monitoring-mass spectrometry (LC/MRM-MS) and later by proximity extension assay (PEA) in a discovery set consisting of 96 newly diagnosed CRC cases and 94 controls free of neoplasms at screening colonoscopy. Two algorithms (one for each measurement method) were derived by Lasso regression and .632+ bootstrap based on 11 proteins that were included in both the LC/MRM-MS and PEA measurements. Additionally, another algorithm was constructed from the same eleven biomarkers plus amphireglin, the most promising protein marker in the PEA measurements that had not been available from the LC/MRM-MS measurements. Lastly the three prediction signatures were validated with PEA in independent samples of participants of screening colonoscopy (CRC (n = 56), advanced adenoma (n = 101), and participants free of neoplasm (n = 102)). Results: The same four proteins were included in all three prediction signatures; mannan binding lectin serine protease 1, osteopontin, serum paraoxonase lactonase 3 and transferrin receptor protein 1, and the third prediction signature additionally included amphiregulin. In the independent validation set from a true screening setting, the five-marker blood-based signature including AREG presented areas under the curves of 0.82 (95% CI, 0.74–0.89), 0.86 (95% CI, 0.77–0.92) and 0.76 (95% CI, 0.64–0.86) for all, early and late stages CRC, respectively. Conclusion: Two different measurement methods consistently identified four protein markers and an algorithm additionally including amphiregulin, a marker measured by PEA only, showed promising performance for detecting early stage CRC in an independent validation in a true screening setting. These proteins may be potential candidates for blood-based tests for early detection of CRC.
format Online
Article
Text
id pubmed-6826652
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68266522019-11-18 Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer Bhardwaj, Megha Gies, Anton Weigl, Korbinian Tikk, Kaja Benner, Axel Schrotz-King, Petra Borchers, Christoph H. Brenner, Hermann Cancers (Basel) Article Objective: Plasma protein biomarkers could be an efficient alternative for population-based screening for early detection of colorectal cancer (CRC). The objective of this study was to evaluate and validate plasma proteins individually and as a signature for early detection of CRC. Methods: In a three-stage design, proteins were measured firstly by liquid chromatography/multiple reaction monitoring-mass spectrometry (LC/MRM-MS) and later by proximity extension assay (PEA) in a discovery set consisting of 96 newly diagnosed CRC cases and 94 controls free of neoplasms at screening colonoscopy. Two algorithms (one for each measurement method) were derived by Lasso regression and .632+ bootstrap based on 11 proteins that were included in both the LC/MRM-MS and PEA measurements. Additionally, another algorithm was constructed from the same eleven biomarkers plus amphireglin, the most promising protein marker in the PEA measurements that had not been available from the LC/MRM-MS measurements. Lastly the three prediction signatures were validated with PEA in independent samples of participants of screening colonoscopy (CRC (n = 56), advanced adenoma (n = 101), and participants free of neoplasm (n = 102)). Results: The same four proteins were included in all three prediction signatures; mannan binding lectin serine protease 1, osteopontin, serum paraoxonase lactonase 3 and transferrin receptor protein 1, and the third prediction signature additionally included amphiregulin. In the independent validation set from a true screening setting, the five-marker blood-based signature including AREG presented areas under the curves of 0.82 (95% CI, 0.74–0.89), 0.86 (95% CI, 0.77–0.92) and 0.76 (95% CI, 0.64–0.86) for all, early and late stages CRC, respectively. Conclusion: Two different measurement methods consistently identified four protein markers and an algorithm additionally including amphiregulin, a marker measured by PEA only, showed promising performance for detecting early stage CRC in an independent validation in a true screening setting. These proteins may be potential candidates for blood-based tests for early detection of CRC. MDPI 2019-09-25 /pmc/articles/PMC6826652/ /pubmed/31557860 http://dx.doi.org/10.3390/cancers11101426 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bhardwaj, Megha
Gies, Anton
Weigl, Korbinian
Tikk, Kaja
Benner, Axel
Schrotz-King, Petra
Borchers, Christoph H.
Brenner, Hermann
Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer
title Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer
title_full Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer
title_fullStr Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer
title_full_unstemmed Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer
title_short Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer
title_sort evaluation and validation of plasma proteins using two different protein detection methods for early detection of colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826652/
https://www.ncbi.nlm.nih.gov/pubmed/31557860
http://dx.doi.org/10.3390/cancers11101426
work_keys_str_mv AT bhardwajmegha evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer
AT giesanton evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer
AT weiglkorbinian evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer
AT tikkkaja evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer
AT benneraxel evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer
AT schrotzkingpetra evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer
AT borcherschristophh evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer
AT brennerhermann evaluationandvalidationofplasmaproteinsusingtwodifferentproteindetectionmethodsforearlydetectionofcolorectalcancer